ADSB-FUB-187

ADSB-FUB-187 is an indazole-based synthetic cannabinoid. It is a potent agonist of the CB1 receptor with a binding affinity of Ki = 0.09 nM and an EC50 of 1.09 nM. It was originally developed by Pfizer in 2009, being example 187 from patent WO 2009/106982. While it is the most tightly binding compound from this patent in terms of Ki, it is not the most potent compound at producing a CB1 mediated pharmacological effect, with at least 17 other compounds from the patent having lower EC50 values.[1]

ADSB-FUB-187
Legal status
Legal status
Identifiers
CAS Number
PubChem CID
Chemical and physical data
FormulaC26H31ClFN5O4S
Molar mass564.07 g/mol g·mol−1
3D model (JSmol)

Legality

Sweden's public health agency suggested classifying ADSB-FUB-187 as hazardous substance on November 10, 2014, following its use as an ingredient in grey-market synthetic cannabis products.[2]

See also


References

  1. "Patent WO/2009/106982 - Indazole derivatives". Cite journal requires |journal= (help)
  2. "Cannabinoider föreslås bli klassade som hälsofarlig vara" (in Swedish). Folkhälsomyndigheten. Retrieved 8 July 2015.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.